EUROGIN 2012
HUMAN PAPILLOMAVIRUS - CERVICAL AND OTHER HUMAN DISEASES

TRANSLATING RESEARCH INTO PRACTICE

Prague (Czech Republic) – July 8-11, 2012

Congress Presidents:
Xavier Bosch (Spain) - Silvia Franceschi (France) - Stina Syrjänen (Finland)

Chairman of the Program Committee: Joseph Monsonego (France)

Advanced Program
Updated May 4, 2012

Sunday, July 8

MTC – Main Training Course

The main training course is designed to provide summaries of the most relevant knowledge on HPV infection and associated diseases with the aim of assisting educators in the health field. The topics covered range from the basic science fundamentals to emerging issues and the clinical uses of screening technologies, prophylactic HPV vaccines and extending to HPV related diseases in external genitalia and head & neck.

Speakers will present only accepted evidence-based scientific information that has been published in the peer-reviewed medical literature.

8:30 – 10:00
MTC1-1 HPV: the cause of cervical cancer
Chair: S. Franceschi
- Defining new strategies for HPV prevention and control
- The burden of HPV associated diseases
- Natural history of HPV infection
- Molecular biology and pathogenesis
- Discussion

M. Goodman USA
S. De Sanjosé Spain
G. Clifford France
J. Doorbar UK

10:00 – 10:30 Coffee Break

10:30 – 12:30
MTC1-2 Screening & vaccination, new evidence
Chair: X. Bosch
- Cervical cancer & cytology based screening programs in Eastern and Central European countries
- Overview of HPV assays and molecular markers
- New strategies of HPV based screening
- HPV vaccination: an update in 2012 (impact – safety – implementation)
- Integration of screening and vaccination in cervical cancers prevention programs
- Discussion

M. Poljak Slovenia
T. Iftner Germany
J. Cuzick UK
J. Paavonen Finland
E. Franco Canada
12:30 – 14:00 Lunch Break

14:00 – 15:30 MTC1-3 Risk based management, current knowledge
Chair: M. Arbyn
- Accuracy of colposcopy W. Prendiville Ireland
- Triage of ASC-US and L-SIL: new evidence W. Huh USA
- HPV and molecular markers in the post-treatment follow-up M. Arbyn Belgium
- Assessing the risk of cervical cancer M. Stoler USA
- Performance and consequences of the treatment of CIN M. Cruickshank UK
- Discussion

15:30 – 16:00 Coffee Break

16:00 – 17:30 MTC2 – HPV infection & associated diseases in non-cervical sites: facts and figures
Chair: S. Syrjänen
- HPV genital infection and diseases in men A. Giuliano USA
- Anal neoplasia: burden, epidemiology and prevention J. Palefsky USA
- The HPV cause of head and neck cancers: epidemiology, burden and new developments M. Gillison USA
- HPV associated diseases in the skin – current knowledge and perspectives H. Pfister Germany
- Discussion

MTC3 – Decision making in colposcopy

8:30 - 10:00 MTC3-1 The fundamentals
Chair: A. Singer – T. Cox
- Principles of colposcopic examination - nomenclature – performance of colposcopy J. Bornstein Israel
- The normal and abnormal cervix (TZ concept, squamous metaplasia, HPV related lesions, ...) A. Singer UK
- The abnormal cervix (the abnormal TZ, HPV related lesions, precancerous lesions, the worse features, invasive cancer, ambiguous situations) S. Quek Singapore
- Glandular lesions – colposcopic features J. Jordan UK
- Colposcopy in special conditions: pregnancy and menopause J. Cortes Spain

Coffee Break

10:00 – 10:30

10:30 – 12:30
- Integration of HPV knowledge in colposcopic practice (features, directed biopsies, genotyping) J. Tan Australia
- Treatment procedures of CIN T. Freeman-Wang UK
- Issues related to follow-up (cancer following treatment L-SIL, adequate interval of follow-up) S. Dexeus Spain
- Psychological aspects of colposcopy D. Harper USA

14:00 – 15:30 MTC3-2 – HPV, colposcopy & lower genital tract diseases
Best practices & management controversies
Chair: J. Cortes – M. Sideri
- Cervix:
  - The technology (images, video, computer-assistance, storage) A. Singer UK
  - The benefit of taking multiple biopsies N. Wentzensen USA
  - Effects of vaccination on colposcopy M. Sideri Italy
  - Cyto & colpo management (ASC-US, ASC-H, L-SIL, W. Huh USA
- Coffee Break
The outcome of women with a negative colposcopy examination: the perspective from the UK screening programme

M. Cruickshank  
UK

Coffee Break

Cervix (continued)

16:00 – 17:30

- HPV results & colpo management (DNA, mRNA, genotyping, p16)
  T. Wright  
  USA
- Vagina & HPV
  M. Hampl  
  Germany
- Vulva & HPV
  E. Joura  
  Austria
- Certification in colposcopy
  J. Jordan  
  UK

16:00 – 17:30

MTC3-3 – Management scenarios: case studies

Chair: W. Huh – M. Roy

A. Singer  
UK
J. Tan  
Australia
J. Cortes  
Spain
**Gynecologic cancer**

Joint course of the European Academy of Cancer (EAGC) and EUROGIN

Chair: P. Bösze, S. Dexeus, T. Maggino

The major aim of the course is to give an update on some of the important topics on cancer of the female genital tract. This includes surgery for cervical cancer, advances of molecular markers and cancer genetics, treatment guidelines and experience with chemoradiation. Emphasis will be put on both theoretical and practical points.

**PART I**

Chair: P. Bösze – T. Maggino

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00</td>
<td>Introduction</td>
</tr>
<tr>
<td>9:15</td>
<td>Homage memory to Antonio Onnis</td>
</tr>
<tr>
<td>9:20</td>
<td>Overview on recent advances in cervical cancer surgical treatment</td>
</tr>
<tr>
<td>9:35</td>
<td>Step-by-step clearance of the pelvic side wall</td>
</tr>
<tr>
<td>10:05</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>10:30</td>
<td>New horizons in prognostic factors of cervical cancer</td>
</tr>
<tr>
<td>10:50</td>
<td>Free papers</td>
</tr>
<tr>
<td>13:00</td>
<td>Lunch Break</td>
</tr>
</tbody>
</table>

**Free papers**

- Historical trends in cervical cancer in Greenland: a 60-year overview
- Burden of HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 in invasive cervical cancer
- HPV16 viral load and risk of in situ and invasive squamous cervical cancer
- The efficacy of conservative management in patients with cervical cancer stage FIGO IA1 treated with laser CO2 therapy
- Expression of vascular endothelial growth factor (VEGF) in the epithelium and stroma of CIN and invasive cervical carcinoma
- Biomarkers and associated factors to invasive cervical cancer stage

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00</td>
<td>Chemoradiation for cervical cancer</td>
</tr>
<tr>
<td>14:30</td>
<td>Can we write the epitaph of the cervical cancer?</td>
</tr>
<tr>
<td>15:00</td>
<td>Current knowledge on the management of vulvar cancer</td>
</tr>
<tr>
<td>15:30</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>16:00</td>
<td>Ovarian cancer: new insights</td>
</tr>
<tr>
<td>16:30</td>
<td>Endometrial cancer – the state of the art</td>
</tr>
<tr>
<td>17:00</td>
<td>Closing remarks</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00</td>
<td>Chemoradiation for cervical cancer</td>
</tr>
<tr>
<td>14:30</td>
<td>Can we write the epitaph of the cervical cancer?</td>
</tr>
<tr>
<td>15:00</td>
<td>Current knowledge on the management of vulvar cancer</td>
</tr>
<tr>
<td>15:30</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>16:00</td>
<td>Ovarian cancer: new insights</td>
</tr>
<tr>
<td>16:30</td>
<td>Endometrial cancer – the state of the art</td>
</tr>
<tr>
<td>17:00</td>
<td>Closing remarks</td>
</tr>
</tbody>
</table>
FC1 – Clinical value of HPV testing
Chair: J. Jeronimo – M. Elfström
Free communications – details to be published soon

FC2 – HPV testing methods
Chair: J.-P. Bogers – B. Hesselink
Free communications – details to be published soon
Joint EUROGIN/WACC Educational Session (Women Against Cervical Cancer)

This session, jointly organized between EUROGIN and WACC, is dedicated to screening & immunization programs, health education and women’s knowledge, awareness, advocacy, as well as to societal and ethical aspects linked to cervical cancer prevention

14:00 – 15:30

Women Against Cervical Cancer (WACC) 1:
Sharing knowledge & education for cervical cancer prevention

Chair: J. Smith – M. Steben

- **Lecture**: 2011 UN declaration on the importance of non-communicable diseases (breast, cervix)
  - A. Ullrich Switzerland
- Barriers to screening in sexually active women in developed countries and in low and middle income countries
  - L. Cadman UK
- Centers of Excellence as a need for improving cervical cancer prevention in low-resources settings
  - J. Jeronimo USA
- Health care databases – a tool to study population effects of HPV vaccination: assessment of HPV vaccination in German health insurance data
  - J. Horn Germany
  - R. Schulze-Rath
- Coverage and compliance of human papillomavirus vaccines in Franche-Comté
  - A. Baudu France
- HPV vaccine acceptability in adult Japanese women: does experience with HPV-related conditions matter?
  - S. Hanley Japan
- Pharmacist vaccination authority of the human papillomavirus vaccine: a state-by-state analysis of the United States of America
  - J. Chung USA
- Colposcopy and cervical pathology education in Russia
  - S. Rogovskaya Russia
- Awareness of HPV, cervical cancer and HPV vaccine in Turkey, attitudes from a Muslim country
  - G. Gönenç Turkey
- Knowledge and health beliefs among Syrian health workers about cervical cancer prevention and early detection
  - D. Al-Khoury Syria
- Risk and preventive behaviours amongst HPV vaccinated and unvaccinated young women
  - L. Sadler UK

16:00 – 17:30

Women Against Cervical Cancer (WACC) 2:
Science facing false ideas:
How to deal with anti-vaccine groups

Chair: J. Cain – R. Konno

- Benefit vs risk of HPV vaccines
  - P.L. Lopalco Sweden
- Side effects: are they of concern?
  - S. Garland USA
- Cost effectiveness issues – are they questionable?
  - M. Brisson Canada
- Ethical issues of HPV vaccine information, is there any deviation?
  - J. Cain USA

Conclusion: Why do we need a widespread HPV vaccine program to prevent cervical cancer in developed and developing countries?

  - E. Franco Canada
OPENING CEREMONY

19:00  Welcome Address
       Presidential messages

       Homage memory to John Sellors

19:20-  Opening lecture
       • Safety issues associated to HPV vaccination: looking back and forward

20:00  WELCOME COCKTAIL
Monday, July 9

Regional Workshop:
Cervical cancer and human papillomavirus in Central and Eastern Europe
Coordination: M. Spaczynski

- Overview: current situation in Eastern European countries
  G. Lazdane  Denmark
- Current status of cervical cancer screening and HPV vaccination implementation in Slovenia
  M. Poljak  Slovenia
- Implementation of HPV vaccination in Eastern European countries
  tbd.
- Cervical cancer in Slovak republic: an overview on actual situation in incidence, mortality, screening and vaccination
  P. Zubor  Slovakia
- Primary and secondary prevention of cervical cancer in Poland. The proposal of new diagnostic methods
  W. Rokita  Poland
- The epidemiology of the cervical cancer and HPV infections in Poland
  E. Nowak-Markwitz  Poland
- Concentration of selected biochemical parameters in blood of pregnant women infected by HPV 16 and 18
  A. Karowicz  Poland
- Cervical cancer screening program in Latvia
  I. Viberga  Latvia
Regional Workshop: Russia
(in Russian language only – see Russian version below)

Coordination: V. Prilepskaya – I. Shabalova

- Current screening situation and perspectives Y. Demina
- Vaccination against HPV and cervical cancer. State of the problem in Russia G. Sukhikh
- The role of physicians and the public education in cervical cancer prevention V. Prilepskaya
- Cytological screening - a look of cytologist I. Shabalova
- The role of HPV testing in management of cervical pathology N. Podzolkova
- Diagnostic and prognostic significance of tumor markers E6 and E7 in cervical intraepithelial neoplasia (CIN) S. Rogovskaya
- Colposcopy role in the diagnosis of diseases associated with HPV L. Ashrafyan
- Management of patients with cervical intraepithelial neoplasia (CIN) M. Kostava
- Management of patients with microcarcinoma (CIS) G. Minkina
- Cervical cancer and pregnancy A. Urmancheeva
- Discussion V. Kozachenko

8:30 – 11:00

8:30 – 11:00

Программа Российской Сессии на Конгрессе EUROGIN в Праге.
Председатели: академик Сухих Г.Т., проф. Прилепская В.Н., проф. Подзолкова Н.М., проф. Урманчеева А.Ф.

- Вакцинация против ВПЧ и цервикального рака. G. Sukhikh Prilepskaya
- Состояние проблемы в России V. Prilepskaya
- Роль образования врачей и населения в профилактике рака шейки матки N. Podzolkova
- Цитологический скрининг глазами цитолога I. Shabalova
- Роль ВПЧ теста в ведении патологии шейки матки S. Rogovskaya
- Диагностическая и прогностическая значимость онкобелков E6 и E7 при цервикальной интраэпителиальной неоплазии. (CIN) L. Ashrafyan
- Роль колпоскопии в диагностике заболеваний ассоциированных с ВПЧ M. Kostava
- Менеджмент пациенток с CIN G. Minkina
- Менеджмент пациенток с микрокарциномой (CIS) V. Kozachenko
- Рак шейки матки и беременность A. Urmancheeva
- Дискуссия

8:00 – 11:00

FC3 – From HPV infection to diseases

Chair: S. De Sanjosé – P. Sparen

Free communications – details to be published soon
MSS – Main Scientific Sessions
Main scientific sessions include keynote lectures giving a broad overview of the essential issues of fundamentals, HPV diseases (broad picture), cancer screening and prevention by the most prominent experts in their respective field.

8:00 – 9:30
MSS1 - HPV and non-genital human cancers: new challenges
Chair: M. Gillison – K. Syrjänen
- **Lecture**: HPV-associated cancers – a growing problem? M. Stanley UK
- HPV and oropharyngeal cancer: current knowledge L. Licitra Italy
- Current management of head & neck cancer H. Mehanna UK
- The role of papillomavirus infection in skin cancer development J.N. Bouwes-Bavinck The Netherlands
- The significance of HPV in the colon & rectum L. Lorenzon Italy

9:30 – 11:00
MSS2 - HPV vaccines – update and perspectives
Chair: J. Paavonen – M. Stanley
- **Introduction**: Evidence on efficacy of HPV vaccines J. Paavonen Finland
- Current knowledge on safety profile of the current HPV vaccines P.L. Lopalco Italy
- Prophylactic vaccines for therapy
- Global impact of HPV vaccination in men & women M. Brisson Canada
- A second-generation broad-spectrum HPV vaccine C. Schellenbacher Austria
- The prospects for an L2 based prophylactic vaccine P. Stern UK
- Therapeutic vaccines S. Pai USA

14:00 – 15:30
MSS3 - HPV based screening strategies: current knowledge
Chair: T. Wright – J. Cuzick
- Cytology with triage by HPV testing G. Ronco Italy
- Triage strategies of HPV positive women H. Berkhof The Netherlands
- HPV genotyping based screening - new evidence M. Stoler USA
- HPV mRNA in primary screening T. Ifner Germany
- Role of p16 in screening F. Carozzi Italy
- Methylation as a screening marker A. Lorincz UK
- HPV screening in low resource settings R. Sankaranarayanan France
- Conclusion: what the clinicians should know W. Huh USA

15:30 – 17:00
MSS4 - New screening experiences and HPV vaccine implementation: lessons learned & actions
Chair: P. Sasieni – N. Broutet
1. **New HPV screening experiences**
   - The Netherlands H. Berkhof The Netherlands
   - Italy G. Ronco Italy
   - Low resource settings J. Jeronimo USA
2. **HPV vaccine implementation: countries deliberation**
   - England K. Soldan UK
   - France I. Parent du Chatelet France
   - Italy P. Bonanni Italy
Oropharyngeal cancer is one of the fastest rising cancers in many countries. This has been attributed to the rise in HPV- head and neck cancer. This new disease entity appears to have significantly better survival outcomes. However, important questions arise regarding its natural history, diagnosis, patient counselling and the best management regimens.

1. What are the available treatments for HPV head & neck cancer?
   a. Surgical treatment options for oropharyngeal cancer (Open surgery and transoral laser or robotic surgery)
   b. Chemoradiotherapy

2. Diagnostic clinical service for HPV head & neck cancer
   a. Setting up a diagnostic service for HPV – head & neck cancer
**b. Pitfalls in the diagnosis of HPV in head & neck cancer**

<table>
<thead>
<tr>
<th>For</th>
<th>Against</th>
</tr>
</thead>
<tbody>
<tr>
<td>R. Sankaranarayanan France</td>
<td>J. Lacau de St. Guily France</td>
</tr>
</tbody>
</table>

**3. Screening for oral and oropharyngeal cancer**

**SEM 2**

**Seminar: HPV in dermatoveneorology**

Jointly organized by EUROGIN and the EADV HPV Task Force

Coordination: G. Gross, J. Hercegova, H. Pfister, M. Skerlev,

HPV is definitely involved in the origin and development of genitoanal cancer of both genders (cervical cancer, vulval cancer, vaginal cancer, anal cancer and penile cancer). HPV types from the betapapillomaviruses (betaPV) genus may play a role in cutaneous squamous cell carcinoma. Functional data support a potential role for betaPV as cocarcinogens with UV, but with mechanisms likely to differ fundamentally to those established in anogenital cancer. HPV-specific antiviral agents are not currently available, but therapeutic anti-HPV vaccines are in development and would be especially appropriate for those persons for whom we can predict a high risk of multiple squamous cell carcinoma. Cutaneous squamous cell carcinomas are an eminent clinical problem in the management of immunosuppressed organ transplant recipients.

### Part I - External genitalia and HPV associated diseases

- Epidemiology and burden of genital warts
  - S. Garland Australia
- Epidemiology and burden of VIN
  - J. Bornstein Israel
- Management
  - Genital warts
    - G. Gross Germany
  - VIN
    - M. Hampl Germany
- Prevention
  - A. Giuliani USA

### Part II - Skin

- Epidemiology of papillomavirus infection and skin cancer in organ transplant recipients
  - J.N. Bouwes-Bavink The Netherlands
- Skin cancer in immunosuppressed patients
  - J. Hercogova Czech Republic
- Molecular mechanisms of keratinocyte transformation
  - M. Tommasino France
- Skin cancer development in beta-HPV transgenic mice
  - H. Pfister Germany
- HPV – skin deep and beyond
  - M. Skerlev Croatia
- Discussion – round table

**SEM 3**

**Seminar: Anal HPV associated diseases**

The incidence of AIN (anal intraepithelial neoplasia) and anal squamous cell carcinoma (SCC) is increasing. Their relationship with HPV is unquestionable. Anal SCC is more prevalent in homosexual males and amongst immunosuppressed groups. The incidence, natural history, risk factors of progression, and best treatment are largely unknown. Early diagnosis and clinical awareness will prevent mutilating surgery.

- Burden - Epidemiology
  - A. Grulich Australia
- Natural history
  - C. Lacey UK
- Anatomy of the anal canal & AIN screening – HPV & AIN
  - P. Mullerat UK
- Management of AIN and anal cancer
  - L. Siproudhis France
- Anal HPV infection and its consequences: Prevention & perspectives
  - J. Palefsky USA
Tuesday, July 10

8:00 – 10:00  MSS5 - Hot topics on HPV infection and diseases – exchanging points of view with experts & public health representatives
Chair: E. Franco – J. Peto

- **Lecture:** Combining HPV vaccination and HPV screening in older women: is it rational?
  - J. Peto UK

  1. **Doubt out: the ultimate debate on HPV vaccines**
  - Reduced / alternative vaccine dose schedules
    - M. Steben Canada
  - The comparative value of bivalent & quadrivalent vaccines
    - M. Jit UK

  2. **HPV screening controversies:**
  - Controversies from the updated guidelines on cervical cancer screening – Round Table
    - Introduction: current barriers to implement HPV screening
      - E. Franco Canada
    - Perspectives of an organized program on the inclusion of HPV testing in cervical cancer screening
      - J. Dillner Sweden
      - E.U.
      - WHO
      - FIGO
    - N. Broutet Switzerland
    - J. Cain USA

  3. **Moving forward forward in comprehensive screening and vaccination programs: concepts for a European implementation trial**
  - X. Bosch Spain

10:00 – 11:00  MSS6 – Advanced topics in screening & vaccination
Chair: P. Bonanni – X. Bosch

- LBC variability of baseline results from different ATHENA sites
  - T. Wright USA

- Monitoring of HPV vaccination effects in Sweden
  - J. Dillner Sweden

- SEHIB study: surveillance of effects of HPV immunization in Belgium
  - S. Weyers Belgium

- Decision by GAVI Alliance to include HPV vaccine in roster of vaccines subsidized for world’s poorest countries
  - K.D. Aung Switzerland

- Optimization screening & vaccination by modeling
  - M. Jit UK

- Vaccine impact in Australia and the need to review screening
  - C. Selvey Australia

14:00 – 15:30  MSS7 - Roadmap 2012 - Cervix and head & neck HPV associated cancers Towards comparative insights
Chair: S. Franceschi – M. Gillison

1. Epidemiologic comparison of cervical cancer and
HPV-associated head and neck cancer
- Similarities and differences in the epidemiology of HPV infection (cervical vs. oral) A. Chaturvedi USA
- Similarities and differences in the epidemiology of cancer X. Castellsagué Spain
- Similarities and differences between cancer of the cervix and the upper aerodigestive tract S. Franceschi France

2. Molecular comparison of cervical cancer and HPV-associated head and neck cancer
- Mechanisms of carcinogenesis M. Tommasino France
- What HPV types should be considered high-risk/oncogenic? Type-specificity of cancer risk M. Goodman USA

3. Comparison of clinical and prevention aspects of cervical cancer and HPV-associated head and neck cancer
- Clinical value of testing for HPV infection and additional markers P. Snijders The Netherlands
- Potential for primary and secondary prevention through HPV vaccination and screening M. Gillison USA

15:30 - 16:30  
**MSS8 – New promising strategies using HPV DNA & mRNA testing**
Chair: T. Iftner – M. Poljak
- Clinical validation of HPV DNA tests in cervical screening D. Heideman The Netherlands
- Risk assessment and clinical impact of 3 HPV assays in cervical cancer screening – the FASE study J. Smith USA
- HPV primary screening compared to co-testing: estimates of efficacy vs. efficiency using the COBAS HPV test M. Stoler USA
- HPV focal: first round screen results from a Canadian population based program E. Franco Canada
- The APTIMA HPV assay versus the Hybrid Capture II test in triage of women with ASC-US or LSIL cervical cytology: a meta-analysis of the diagnostic accuracy M. Arbyn Belgium

17:00 – 18:00  
**MSS9 – The emerging role of genotyping 1**
Chair: M. Stoler – K. Cuschieri
- LSIL age stratification (ATHENA baseline data) J. Cuzick UK
- Meta-analysis HPV16-18 in triage ASC-US/LSIL M. Arbyn Belgium
- Analytical and clinical performance of the APTIMA® HPV 16 18/45 genotype assay for detection of HPV 16, 18 and 45 mRNA S. Joo USA
- Clinical significance of the dynamic profile of type-specific viral load C. Depuydt Belgium
- Diagnostic accuracy of testing for high-risk (HR) human papillomavirus (HPV) types 16, 18 and 45 in precancerous cervical lesions: results of a 3-years prospective study S. Tiews Germany

18:00 -  
**MSS10 – Discover the value of molecular markers**
Scientific Sessions
These concurrent sessions feature presentations of selected abstracts on new findings covering a broad range of topics related to genital cancer prevention and management of patients with HPV-associated diseases.

8:00 - 9:30  SS1 – Recent advances on cervical cancer screening
Chair: G. Ronco – N. Wentzensen
- Screening interval: co-testing vs cytology, a 5 year analysis  T. Cox USA
- Is cytology with adjunctive staining for p16/Ki67 make HPV testing superfluous in cervical cancer screening  G. Ronco Italy
- Randomised implementation of primary HPV screening in Sweden  C. Eklund Sweden
- Screening intervals in HPV-negative women  M. Elfström Sweden
- VIA vs HPV-based screening in developing countries  R. Sankaranarayanan France
- Methylation markers for the triage of HPV positive women  N. Wentzensen USA

9:30 - 11:00  SS2 – Advantages and barriers to self-sampling HPV screening
Chair: J. Belinson – J. Bornstein
- HPV detection in self-collected vaginal specimen in Sweden  U. Gyllensten Sweden
- A new paradigm for cervical cancer screening based on self-sampling  J. Belinson USA
- HPV testing in non-attendees of cervical screening  D. Heideman The Netherlands
- Molecular triage of HPV positive women in self-sampled material  B. Hesselink The Netherlands
- Self-collection for care HPV testing: results from multi-country experiences  J. Jeronimo USA
- Self-collection of vaginal specimens for HPV testing in cervical cancer prevention: the MARCH trial  A. Lorincz UK

8:00 - 9:30  SS3 – Advanced topics in epidemiology
Chair: A. Giuliano – S. de Sanjóé
- Burden of cervical cancer in Europe – Western vs Eastern European countries  E. Weiderpass Vainio Norway
- Survival from screen-detected vs symptomatic cervical cancer
  B. Andrae  Sweden
- Susceptible populations
  G. Clifford  France
- Cervical cytokines and HPV clearance
  M. Goodman  USA
- Redetection of HPV: reactivation vs latency
  A.B. Moscicki  USA
- Comparative epidemiology HPV infection in men & women
  A. Giuliano  USA
- HPV infection in immigrant population
  P. Sparen  Sweden

14:00 – 15:30
SS4 – Controversial issues in the field of HPV: how can models help our understanding?
Chair: M. Brisson – M. Jit
- Introduction
  M. Brisson  Canada
- Male vaccination: is it cost-effective and can it reduce inequities?
  J. Bogaards  The Netherlands
- Cross-protection: how do we interpret trial data, and how important is it at a population-level?
  T. Malagon  Canada
- Re-infection: how can it affect the success of HPV vaccine programs?
  A. Vink  The Netherlands
- 2-dose vs. 3-dose HPV vaccination: can a 2-dose strategy be the best use of resources?
  M. Jit  UK
- Serotype replacement: should we be worried?
  M.C. Boily  UK
- Vaccine efficacy, transient infection and herd immunity: implications for the impact of vaccination
  D. Regan  Australia

15:30 – 16:30
SS5 – Emerging issues in head & neck cancers
Chair: J. Lacau de St. Guily – L. Licitra
- Incidence and risk factors for head and neck cancer and cervical cancer among HIV-infected individuals in North America
  G. D’Souza  USA
- HPV serology and head & neck cancers: new evidence
  M. Pawlita  Germany
- Differences in the epidemiology and risk factors of HPV+ and HPV-ve head and neck cancers
  A. Chaturvedi  USA
- Differences between HPV+ve and HPV-ve head and neck cancers at the molecular level
  R. Brakenhoff  The Netherlands
- Are we encountering an HPV epidemic of OSCC – the Stockholm – data
  T. Dalianis  Sweden
- Treatments for HPV+ vs HPV-ve disease – should they be different?
  L. Licitra  Italy

17:00 – 18:00
SS6 – Recent progress & questions related to HPV vaccines
Chair: M. Steben – M. Einstein
- Quadrivalent vaccine - long-term follow-up studies
  M. Steben  Canada
- Bivalent vaccine - long-term follow-up studies
  J. Paavonen  Finland
- Main challenges in trying to compare both vaccines
  P. Bonanni  Italy
- Unanswered questions from the available clinical studies
  E Franco  Canada
- Epidemiology and disease burden considerations
  X. Castellsagué  Spain
in future health technology assessments for HPV vaccination in Europe

18:00 – 19:00

SS7 – Non-cervical HPV associated diseases, current knowledge
Chair: J. Palefsky – C. Lacey
- HPV, skin & sex
  M. Skerlev Croatia
- Update on HPV-associated oral cancer in men
  A. Chaturvedi USA
- New approaches to the treatment of AIN
  J. Palefsky USA
- Penile HPV infection and disease in HIV-infected men
  C. Lacey UK
- Female HPV data
  R. Crawford France
- Economic burden of non-cervical human papillomavirus-related cancers in Western Europe: a scoping review
  N. Largeron France

14:00 – 15:15

SS8 – Update on HPV vaccines
Chair: F. Martinon Tores – A. Szarewski
- Use of HPV prophylactic vaccines in infected persons
  M. Steben Canada
- HPV vaccination with Cervarix in adult women
  A. Szarewski UK
- No adverse signals observed after exposure to human papillomavirus type 6/11/16/18 vaccine during pregnancy: 5 years data from the pregnancy registry
  F. Lievano USA
- How best to measure vaccine effectiveness?
  S. Garland Australia
- 48-month efficacy of the HPV-16/18 ASO4-adjuvanted vaccine in young Japanese women
  R. Konno Japan
- Gardasil® and autoimmune disorders: safety assessment using the PGRx information system
  L. Grimaldi-Bensouda France

15:15 – 16:30

SS9 - New horizons in anti-viral drugs & therapeutic vaccines
Chair: P. Stern – S. van der Burg
- Lecture: antiviral agents against HPV: recent advances
  J. Archambault Canada
- Local immune response in HPV induced cancer
  H. Van der Burg The Netherlands
- Long peptide vaccine
  M. Van Poelgeest The Netherlands
- Investigation of the activity of the HIV protease lopinavir against HPV
  I. Hampson UK
- Cidofovir/imiquimod for the treatment of VIN
  A. Tristram UK
- New approaches for second generation HPV vaccines: chimeric p16INK4a-HPV16 L1 particles
  F. Faulstich Germany

17:00 – 18:00

SS10 – Recent developments in molecular markers
Chair: A. Lorincz – M. von Knebel Doeberitz
- P16INK4a immunocytochemistry versus HPV testing for triage of women with ASC-US or
LSIL cervical cytology: a systematic review and meta-analysis

- p16/Ki-67 dual-stained cytology using ThinPrep liquid-based cytology – sub-analyses of more than 9,000 PALMS study participants
  
- Resolution of ASCUS into “Normal” or “LSIL” diagnoses using OncoTect 3Dx with combined morphologic/biomarker parameters and bioinformatics

- Detection and quantification of HPV E7 oncoproteins in cervical smears

- Validation of the triage value of HPV16 DNA methylation in the CRISP cohort

- The methylome of episomal and integrated HPV 16 genomes in pre-invasive and invasive cervical lesions

C. Bergeron  France

B. Patterson  USA

B. Lener  Austria

A. Brentnall  UK

M. Von Knebel-Doeberitz  Germany

18:00 – 19:15

SS11 – New insights in low income countries
Chair: J. Jeronimo – R. Sankaranarayanan

- Rights, ethics and cervical cancer: barriers to prioritizing cervical cancer control in low resource settings
  
- Progress in improvement of cervical cancer prevention in countries of Eastern Europe and Central Asia – triggers and barriers

- Cost-effectiveness of cervical cancer prevention in the Eastern European region

- HPV RNA testing among high-risk women in Nairobi, Kenya

- Perspective on treatment of cervical neoplasia in low- and medium-resource countries

- How molecular testing will change the way we screen in developing countries

J. Cain  USA

G. Lazdane  Denmark

H. Berkhof  The Netherlands

J. Smith  USA

R. Sankaranarayanan  India

J. Jeronimo  USA

9:30 – 11:15

FC4 – Diagnosis & Management
Chair: T. Maggino – M. Cruickshank
Free communications – details to be published soon

8:00 – 9:30

FC5 – Molecular Markers
Chair: C. Depuydt – M. Tommasino
Free communications – details to be published soon

9:30 – 10:30

FC6 – HIV/STI and HPV infections
Chair: C. Lacey – K. D'Hauwers
Free communications – details to be published soon

10:30 – 11:30

FC7 – Anal HPV diseases
Chair: L. Siproudhis – P. Mullerat
Free communications – details to be published soon
14:00 – 15:00  FC8 – Cytological screening
            Chair: K. Syrjänen – F. Borruto
            Free communications – details to be published soon

15:00 – 16:30  FC9 – HPV screening
            Chair: V. Dalstein – D. Heidemann
            Free communications – details to be published soon

17:00 – 19:15  FC10 – New challenges in HPV associated head &
               neck cancers
            Chair: A. Psyrri – T. Dalianis
            Free communications – details to be published soon
Wednesday, July 11

8:00 - 9:30
MSS11 - Heterogeneity of CIN 3
Chair: G. Clifford – D. Harper
- HPV-specific natural history
  G. Clifford France
- The heterogeneity of CIN3: understanding why not all CIN3 progresses to cancer
  M. Stoler USA
- Viral and host markers of CIN3 heterogeneity
  N. Wentzensen USA
- Management follow-up
  D. Harper USA
- The role of naturally-acquired antibodies and HPV type in the natural history of CIN
  X. Castellsagué Spain

9:30 - 11:00
MSS12 - HPV 16 vs other HR HPV carcinogenic infection: the critical issues
Chair: S. Franceschi
- HPV type distribution by severity of lesion
  S. Franceschi France
- Natural history and disease heterogeneity
  N. Wentzensen USA
- Cross sectional and longitudinal association with high-grade CIN
  G. Ronco Italy
- Combination of findings from screening and in vitro transformation data
  P. Snijders The Netherlands
- HPV types in the context of HPV vaccination
  J. Dillner Sweden

11:00 - 12:30
MSS13 - HPV DNA & mRNA testing 2
Chair: F. Carozzi – C. Clavel
- Performance characteristics of a fully automated screening and genotyping HPV test - The BD HPV GT Assay on Viper™ LT
  B. Nussbaumer USA
- A large UK hospital’s experience with the Hologic Cervista® MTA (Medium Throughput Automation)
  K. Denton UK
- Comparison of APTIMA and HC2 in routine screening in Germany
  T. Iftner Germany
- HPV testing in the diagnosis and follow-up of CIN patients: comparison of different methods
  M. Sideri Italy
- The HR-HPV testing in follow-up of cytological abnormalities with negative colposcopy
  F. Carozzi Italy
- Performance of HPV DNA, E6/E7 mRNA and p16RINK/6/Ki-67 protein co-expression as a triage tool for LSIL/ASCUS
  C. White Ireland
- Scottish Test of Cure Study - HPV test comparisons (STOCS-H)
  H. Cubie UK

12:30 - 14:00
MSS14 - Emerging issues in HPV genotyping
Chair: A. Szarewski - W. Huh
- PREDICTOR 2 study
  A. Szarewski UK
- VALGENT 1: findings from Belgium
  C. Depuydt Belgium
- VALGENT 3
  M. Poljak Slovenia
- Performance of the digene HPV genotyping PS test for the detection of HPV 16, 18, and 45
  H. Thai USA
**Comparison of cobas PCR and HC2 HPV testing in a German routine laboratory**  
H. Ikenberg  
Germany

| 8:00 – 9:30 |
| SS12 - Vaccines 4 – Adverse effects and impacts  
Chair: A. Chaturvedi – M. Pitts |
| **Population impact after opportunistic quadrivalent HPV vaccination in Sweden 2007-2011**  
A. Wikström  
Sweden |
| **Could a 9-valent vaccine make a difference?**  
C. Schellenbacher  
Austria |
| **Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against HPV types associated with genital warts**  
A. Szarewski  
UK |
| **The incidence of anogenital warts in Germany after introduction of HPV vaccination**  
R. Schulze-Rath  
Germany |
| **Incidence of genital warts in Sweden pre and post quadrivalent HPV vaccine availability**  
P. Sparen  
Sweden |
| **Occurrence of adverse events after quadrivalent HPV vaccination in Denmark and Sweden**  
L. Arnheim-Dahlström  
Sweden |
| **Quadrivalent HPV-vaccine population effectiveness on genital warts: a population-based study in over 2.2 million women**  
E. Herweijer  
Sweden |

| 9:30 – 11:00 |
| SS13 – Advanced topics in immunology and molecular biology  
Chair: M. Pawlita |
| **Lecture**: molecular evidence for carcinogenicity of PHR-HPV types in cervical carcinoma  
M. Pawlita  
Germany |
| **Immunogenicity and safety of a candidate tetravalent human oncogenic papillomavirus vaccine**  
G. Leroux-Roels  
Belgium |
| **Molecular basis of papillomavirus latency**  
J. Doorbar  
UK |
| **HPV vaccines update: state of the science immunogenicity of HPV2 vs. HPV4**  
M. Einstein  
USA |
| **Characterization of the local immune response in cervical and vulvar intraepithelial lesions**  
M. Sauer  
Germany |

| 11:00 – 12:30 |
| SS14 - Quality assessment of HPV testing  
Chair: J. Dillner – H. Cubie |
| **Assessment of competence to undertake HPV testing in a cervical screening programme**  
H. Cubie  
UK |
| **Role of national HPV reference laboratories**  
J. Dillner  
Sweden |
| **HPV-cytology correlation as QC for cytology**  
M. Arbyn  
Belgium |
| **Which HPV DNA tests can be considered as clinically validated**  
T. Iftner  
Germany |

| 12:30 – 14:00 |
| SS15 - HPV testing methods: recent developments  
Chair: P. Snijders – C. Mougin |
| **Novel methods of genotyping, using deep sequencing or mass spectrometry**  
J. Dillner  
Sweden |
| **Clinical validation of HPV genotyping tests**  
M. Arbyn  
Belgium |
Clinical validation of HPV genotyping tests using the Scottish cervical cytology biobank

Are all HPV target regions created equal? - a critical look at the commonly used HPV target regions and their influence on assay performance

Validation of the QIAsymphony DSP AXpH DNA system as for PreservCyt® testing on the Hybrid Capture 2 rapid capture system

Comparison of automated extraction vs manual conversion of LBC samples for HC2 HPV testing

Effect of mixed infections on the detection of high-risk HPV types

Novel co-factors for heterosexual HPV transmission

Sources of genital HPV infection

Evidence of anogenital oral transmission

Circumcision to prevent male HPV and HIV infection

Opportunities for the prevention of the heterosexual transmission (susceptibility, genetics, immunity)

Interaction between chlamydia trachomatis and high-risk HPV in the development of cervical neoplasia

Validation of cervical cancer screening methods in HIV positive women from Johannesburg

HPV vaccines in HIV infected individuals

Anal HPV and anal cancer in people with HIV

HPV vaccines in HIV seropositive individuals

Current status of cervical cancer prevention programs worldwide among HIV seropositive individuals

HPV oncogene mRNA testing for the detection of anal dysplasia in HIV-infected men

HPV increasing the risk of HIV

Age issues of HPV screening

Primary screening scenarios based on baseline
data from ATHENA

- Triage of HPV-positive women: cytology or HPV genotyping? L. Dillner Sweden
- Methylation as a triage marker for cytology negative HPV positive women R. Steenbergen The Netherlands
- p16/Ki-67 dual-stain as a triage marker for cytology-negative/HPV-positive women H. Ikenberg Germany
- Other markers for HPV screening triage J. Doorbar UK
- mRNA as a triage for HPV + cyto - women M. Reuschenbach Germany

13:00 – 14:30 SS19- Contemporary management of HPV associated genital diseases
Chair: E. Siegler – M. Roy

- The value of random biopsies T. Cox USA
- Leep conisation increases the risk for adverse pregnancy outcome: how much? M. Jakobsson Finland
- Managing CIN3 in pregnancy E. Siegler Israel
- Pap smears classified as atypical glandular cells (AGC) – outcomes and management in pregnancy J. Slama Czech republic
- An innovative treatment of HPV and cervical neoplasia – safety considerations V. Dvorak Czech republic
- Long-term follow-up of posterior vestibulectomy in the treatment of localized provoked vestibulodynia P. Tommola Finland
- Agreement between colposcopic impression and histology among hrHPV16 positive women J. Louwers The Netherlands
- Post-colposcopy follow-up of women with negative cervical biopsy – a prospective study S. Sorbye Norway
- Risk of cervical cancer after treatment of cervical intraepithelial neoplasia: role of loss to follow-up M. Rebolj Denmark
- Vaginal intraepithelial neoplasia (VaIN 2/3): comparing clinical outcomes of treatment with intravaginal estrogen H. Rhodes USA
- A hand-held electrical impedance spectroscopy device improves colposcopy performance J. Tidy UK
**Comprehensive Colposcopy Course**

(Separate registration required)

**Coordinators:** A. Singer – J. Jordan

- Introduction
- The normal cervix: a prerequisite to understand the abnormal cervix
- Update on the pathology of cervical precancer
- QUESTIONS
- How do we diagnose cervical precancer; cytology, HPV testing, colposcopy and other methods
- The abnormal cervix; colposcopy and methods of examination
  - Video case presentations (Faculty)

**COFFEE**

- Microinvasion and glandular cervical disease and other difficult colposcopic examination
- Treatment of cervical precancer; who, why and how

**QUESTIONS**

**COFFEE AND CAKE**

- Current practice algorithms
- Case presentation (interactive session); cytology, colposcopy, pathology and treatment
- SUMMARY AND CLOSE

---

**Vulvar diseases course + accreditation**

**Coordinator:** J. Bornstein

The satellite course on vulvar disease has been designed for clinicians who currently treat or diagnose women with cervical and vaginal disease. The faculty will discuss current knowledge of vulvar benign and premalignant disease, from various aspects: pathophysiology, clinical features, histological appearance, and treatment. Common and difficult cases will be presented and discussed

- Introduction
- Benign HPV lesions: diagnosis and treatment
- Vulvar pain, etiology and diagnosis
- VIN – diagnosis, terminology
- VIN – prevention and treatment
- Vulvar carcinoma - current treatment
- Vulvar pain: surgical and non-surgical treatments
- Psycho-sexual aspects of vulvar disease
- Summary and close

**Speakers:**
- J. Bornstein – Israel
- M. Hampl – Germany
- J. Bornstein – Israel
- M. Sideri – Italy
- E. Joura – Austria
- M. Roy – Canada
- J. Bornstein – Israel
- M. Steben – Canada
Best practices in publishing clinical & public health research
Satellite Short Course

Instructor: Dr. Eduardo L. Franco, James McGill Professor, Departments of Oncology and of Epidemiology; Interim Chair, Department of Oncology, and Director, Division of Cancer Epidemiology, McGill University, Montreal, Canada.

The objectives of this short course are:

1) to provide an overview of principles of good scientific practice as applied to research on human subjects;
2) to discuss elements of scientific reasoning that are used in clinical and public health research and mentorship;
3) to discuss the process of research communication and publishing;
4) to discuss the key features that enhance the quality of a paper and its value to the scientific community;
5) to discuss rules of authorship, strategies to avoid conflict, criteria to select journals, and issues to be avoided.

Instruction will be via interactive lecture to take advantage of students' own experiences as authors; emphasis on issues pertaining to study design, ethics, data analysis, scientific integrity, and strategies of communicating and interpreting results of clinical and public health research.

This course is intended for public health practitioners, epidemiologists, and other clinical researchers in the early stages of their careers or those who are switching from clinical or public health practice to research. Public health practitioners and policymakers may also find the contents valuable in understanding the process of scientific research and publishing. Researchers whose mother tongue is not English may find the course particularly helpful in assisting them to navigate the process of preparing, submitting, and revising manuscripts for publication in international biomedical journals.

Note about the instructor:

Dr. Franco has extensive experience as an author, editor, and overseeing the publication process in epidemiology and clinical research in oncology. He has published over 340 scientific articles, 50 chapters, and two books on cancer epidemiology and prevention. He has served as Guest Editor for nine journal supplement issues on the topic of his research (cancer epidemiology and prevention). He has served in the editorial board of the following journals: American Journal of Epidemiology (1993-98); Cancer Detection and Prevention (2001-08), Cancer Epidemiology, Biomarkers & Prevention (1995-); Epidemiology (1993-2009), International Journal of Cancer (2009-11), Medical and Pediatric Oncology (2000-04), Oral Diseases (2005-), PLoS-Medicine (2004-), Preventive Medicine (2008-) among other journals. He has also served as ad hoc manuscript reviewer for dozens of other biomedical journals.